19 completed. 19 Phase 3.
By phase and status
Follow telaprevir: new trials by email Literature Review of telaprevir trials Research Report on telaprevir
Trials (filtered) newest first · largest first
All 19 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT) Ribavirin, Telaprevir - HIV Phase 3 Completed 20 2014-01-01 2017-04-12 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults ABT-450/r/ABT-267, ABT-333, Ribavirin, Pegylated Interferon a-2a (PegINF) - Chronic Hepatitis C Infection Phase 3 Completed 148 2013-06-01 2018-06-06 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before ABT-450/r/ABT-267, ABT-333, Ribavirin, Telaprevir - Chronic Hepatitis C Infection Phase 3 Completed 311 2013-03-01 2018-06-06 Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin - Hepatitis C Phase 3 Completed 444 2013-01-01 2015-10-09 A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects Daclatasvir, Asunaprevir, Ribavirin - Hepatitis C Virus Infection Phase 3 Completed 258 2012-11-01 2015-10-09 Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin - Hepatitis C Virus Phase 3 Completed 881 2012-06-14 2019-07-31 Telaprevir Open-Label Study in Co-Infected Patients Telaprevir - Hepatitis C, Chronic Phase 3 Completed 122 2012-06-01 2016-08-18 An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) Telaprevir, Ribavirin, Pegylated-Interferon-alfa-2a - Chronic Hepatitis C Phase 3 Completed 163 2012-04-01 2016-05-05 An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation Telaprevir, Pegylated interferon alfa-2a, Ribavirin - Chronic Hepatitis C Virus (HCV) Infection Phase 3 Completed 74 2012-02-01 2016-06-30 Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection Daclatasvir, Telaprevir, Peginterferon alfa-2a - Hepatitis C Phase 3 Completed 605 2012-01-01 2016-06-03 Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C Telaprevir, Pegylated-interferon-alfa-2a, Ribavirin - Genotype 1 Chronic Hepatitis C Phase 3 Completed 36 2012-01-01 2015-01-30 VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection Ribavirin, Telaprevir, Pegylated interferon alfa-2a - Genotype 1 Chronic Hepatitis C, Treatment Naive Phase 3 Completed 744 2010-12-01 2014-06-04 VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV) - Hepatitis C, Chronic Phase 3 Completed 90 2010-04-01 2013-05-08 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy MP-424, Ribavirin, Peginterferon Alfa-2b - Hepatitis C Phase 3 Completed 32 2008-12-01 2026-01-06 Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy MP-424, Ribavirin, Peginterferon Alfa-2b - Chronic Hepatitis C Phase 3 Completed 109 2008-11-01 2026-01-06 Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C MP-424, Ribavirin, Peginterferon Alfa-2b - Hepatitis C Phase 3 Completed 189 2008-11-01 2026-01-06 A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment Telaprevir, Peg-IFN-alfa-2a, Ribavirin - Hepatitis C, Chronic Phase 3 Completed 663 2008-10-01 2014-01-22 A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response telaprevir, ribavirin, peginterferon alfa-2a - Hepatitis C Phase 3 Completed 540 2008-10-01 2021-03-26 A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin - Hepatitis C Phase 3 Completed 1095 2008-03-01 2014-08-08
Conditions studied Hepatitis C (15) · Hepatitis C, Chronic (9) · Fibrosis (1) · Infections (1)
Sponsors Bristol-Myers Squibb (4) · Janssen-Cilag International NV (4) · Tanabe Pharma Corporation (3) · AbbVie (2) · Janssen Infectious Diseases BVBA (2) · Vertex Pharmaceuticals Incorporated (2) · St Stephens Aids Trust (1) · Tibotec BVBA (1)
Countries United Kingdom (11) · France (9) · Germany (9) · Spain (9) · Poland (8) · United States (8) · Belgium (7) · Australia (6) · Austria (6) · Brazil (6) · Israel (6) · Russia (6) · Canada (5) · Japan (5) · Italy (4)
Top investigators Fumitaka Suzuki, MD (3) · Hendrik Reesink, MD, PhD (1) · Kenneth Sherman, MD, PhD (1) · Mark Nelson, Dr (1) · Michael Adler, MD, PhD (1) · Yan Luo, MD (1) · Yan Luo, MD, PhD (1)
Results publications PMID 22239511 , PMID 26321288 , PMID 21696307 , PMID 21696308 , PMID 21827730 , PMID 21916639 , PMID 23321318 , PMID 23743475 , PMID 24316262 , PMID 24382638 , PMID 24486089 , PMID 25653396 , PMID 25712364 , PMID 26416471 , PMID 26483516 , PMID 27327078
NIH funding 2009 (1)